Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734915 · ClinicalTrials.gov registry record
Detecting EGFR T790M Mutations From Circulating Tumor Cells
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 40
- Enrollment target
NCT01734915: Completed study, sponsored by Massachusetts General Hospital.
NCT01734915 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01734915 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an experimental device. Using this device, the investigators will test participants' blood to try and find CTCs with the EGFR mutation and compare them with the results from the biopsy your doctor has recommended. The long-term goal of this research is to develop a way to test for the EGFR mutation that is less invasive than a tumor biopsy.
Interventions
- DEVICE Circulating tumor cell chip
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01734915
The ClinicalTrials.gov registry entry for NCT01734915 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Circulating tumor cell chip is the first listed.
NCT01734915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01734915 about?
NCT01734915 is a clinical study titled "Detecting EGFR T790M Mutations From Circulating Tumor Cells". The purpose of this research study is to determine if the EGFR mutation can be detected in CTCs. CTCs are cancer cells that are shed from solid tumors and float freely in the bloodstream. A device called the CTC-chip has been developed to find CTCs in the blood of patients with cancer. This is an ex...
What is the current status of trial NCT01734915?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2012-11. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01734915?
The interventions under investigation include: Circulating tumor cell chip (DEVICE).
Who is sponsoring clinical trial NCT01734915?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.